Anzeige
Mehr »
Freitag, 18.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHB | ISIN: US03828A1016 | Ticker-Symbol: 2UV
Tradegate
17.07.25 | 17:00
0,395 Euro
+5,52 % +0,021
1-Jahres-Chart
APPLIED THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APPLIED THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3900,41017.07.
0,3940,41517.07.

Aktuelle News zur APPLIED THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Applied Therapeutics promotes two executives to leadership roles31
17.06.Applied Therapeutics Announces Key Leadership Appointments17
APPLIED THERAPEUTICS Aktie jetzt für 0€ handeln
12.06.Applied Therapeutics, Inc. - 8-K, Current Report10
18.05.Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting310Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute...
► Artikel lesen
14.05.Applied Therapeutics GAAP EPS of -$0.15 beats by $0.0319
13.05.Applied Therapeutics, Inc. - 8-K, Current Report9
13.05.Applied Therapeutics Reports First Quarter 2025 Financial Results201- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society...
► Artikel lesen
09.05.Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting26
24.04.Applied Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans19
15.04.Applied Therapeutics, Inc. - 10-K, Annual Report12
15.04.Applied Therapeutics GAAP EPS of -$0.76 beats by $0.57, revenue of $0.5M misses by $0.05M34
14.04.Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results234- Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025...
► Artikel lesen
31.03.Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission25
31.03.Applied Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4059
19.03.Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer18
19.03.Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer221NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced...
► Artikel lesen
10.02.Applied Therapeutics, Inc. - 8-K, Current Report24
21.01.Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality24
20.12.24Applied Therapeutics Appoints John H. Johnson as Executive Chairman445Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc....
► Artikel lesen
29.11.24ROUNDUP/Aktien New York Schluss: Gewinne am 'Black Friday' - Teils mit Rekorden6.633NEW YORK (dpa-AFX) - Nach der Feiertagspause wegen Thanksgiving haben die US-Leitindizes am Freitag den verkürzten Handel mit Gewinnen beendet. Der Dow Jones Industrial testete im Verlauf erneut die...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,5,59